Monopar Therapeutics (MNPR) News
NASDAQ: MNPRHealth CareBiotechnology: Pharmaceutical PreparationsUSD
69.00-1.29 (-1.84%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
MNPR news summary
We found 3 recent headlines mentioning Monopar Therapeutics (MNPR): 0 in the past week and 3 in the past 30 days, most often from GlobeNewswire, Nasdaq. For price context, MNPR is down 1.84% at $69.00. The most recent story, "Monopar Therapeutics Inc. Reports Third Quarter 2026 Financial Results and Progresses ALXN1840 NDA Submission", was published by Nasdaq on Nov 13, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Monopar Therapeutics headlines
- Monopar Therapeutics Inc. Reports Third Quarter 2026 Financial Results and Progresses ALXN1840 NDA SubmissionMonopar Therapeutics Inc. reported its financial results for the third quarter ended September 30, 2026. The company recorded a net loss of $6.2 million, or $0.72 per share, compared to a net loss of…Nasdaq
- Monopar Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business UpdatesWILMETTE, Ill., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company developing innovative treatments…GlobeNewswire
- Monopar Presents Data Highlighting Residual Disease Burden in Treatment-Experienced Wilson Disease Patients and Long-Term Molybdenum Safety Data for ALXN1840 at AASLD – The Liver Meeting® 2026WILMETTE, Ill., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments…GlobeNewswire